Кристи Фанк - Грудь. Руководство пользователя [litres]

S. L. Showalter et al., “Lifestyle Risk Factors Associated with Arm Swelling among Women with Breast Cancer,” Annals of Surgical Oncology 20, no. 3 (March 2013): 842–849.

C. M. Ferguson et al., “Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer,” Journal of Clinical Oncology 34, no. 7 (2015): 691–698.

S. Dhesy-Thind et al., “Use of Adjuvant Bisphosphonates and Other Bone Modifying Agents in Breast Cancer,” Journal of Clinical Oncology 35, no. 18 (June 2017): 2062–2081.

K. D. Crew, “Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer,” Journal of Clinical Oncology 25, no. 25 (September 2007): 3877–3883.

M. Seretny et al., “Incidence, Prevalence, and Predictors of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-analysis,” PAIN 155, no. 12 (2014): 2461–2470.

D. Irvine et al., “The Prevalence and Correlates of Fatigue in Patients Receiving Treatment with Chemotherapy and Radiotherapy,” Cancer Nursing 17, no. 5 (October 1994): 367–378.

J. E. Bower et al., “Fatigue in Breast Cancer Survivors: Occurrence, Correlates, and Impact on Quality of Life,” Journal of Clinical Oncology 18, no. 4 (February 2000): 362.

D. S. Dizon, “Quality of Life after Breast Cancer: Survivorship and Sexuality,” The Breast Journal 15, no. 5 (September – October 2009): 500–504.

J. E. Dew, B. G. Wren, and J. A. Eden, “A Cohort Study of Topical Vaginal Estrogen Therapy in Women Previously Treated for Breast Cancer,” Climacteric 6, no. 1 (March 2003): 45–52.

A. Kendall et al., “Caution: Vaginal Estradiol Appears to Be Contraindicated in Postmenopausal Women on Adjuvant Aromatase Inhibitors,” Annals of Oncology 17, no. 4 (April 2006): 584–587.

A. Chang et al., “The Effect of Herbal Extract (EstroG‐100) on Pre‐, Peri‐ and Post‐Menopausal Women: A Randomized Double‐Blind, Placebo‐Controlled Study,” Phytotherapy Research 26, no. 4 (2012): 510–516.

V. D. E. Simone and O. Pagani, “Pregnancy after Breast Cancer: Hope after the Storm,” Minerva Ginecologica 69, no. 6 (December 2017): 597–607.

H. A. Azim et al., “Safety of Pregnancy Following Breast Cancer Diagnosis: A Meta-analysis of 14 Studies,” European Journal of Cancer 47, no. 1 (2011): 74–83.

P. Fani, “Breastfeeding and Breast Cancer,” Health Science Journal 6, no. 4 (October – December 2012): 610.

O. G. Palesh et al., “A Longitudinal Study of Depression, Pain, and Stress as Predictors of Sleep Disturbance among Women with Metastatic Breast Cancer,” Biological Psychology 75, no. 1 (April 2007): 37–44.

F. N. Bokhari et al., “Pilot Study of a Survey to Identify the Prevalence of and Risk Factors for Chronic Neuropathic Pain Following Breast Cancer Surgery,” Oncology Nursing Forum 39, no. 2 (March 2012): E141–E149.

M. C. Lauridsen, P. Christiansen, and I. B. Hessov, “The Effect of Physiotherapy on Shoulder Function in Patients Surgically Treated for Breast Cancer: A Randomized Study,” Acta Oncologica 44, no. 5 (2005): 449–457.

M. T. Lacomba et al., “Axillary Web Syndrome after Axillary Dissection in Breast Cancer: A Prospective Study,” Breast Cancer Research and Treatment 117, no. 3 (2009): 625–630.

K. M. Mustian et al., “A 4-Week Home-Based Aerobic and Resistance Exercise Program during Radiation Therapy: A Pilot Randomized Clinical Trial,” Journal of Supportive Oncology 7, no. 5 (September – October 2009): 158–167; I. CantareroVillanueva et al., “Effectiveness of Water Physical Therapy on Pain, Pressure Pain Sensitivity, and Myofascial Trigger Points in Breast Cancer Survivors: A Randomized, Controlled Clinical Trial,” Pain Medicine 13, no. 11 (November 2012): 1509–1519.

P. F. Pradat et al., “Radiation-Induced Neuropathies: Collateral Damage of Improved Cancer Prognosis,” Revue Neurologique 168 (2012): 939–950.

C. P. Watson and R. J. Evans, “The Postmastectomy Pain Syndrome and Topical Capsaicin: A Randomized Trial,” Pain 51, no. 3 (December 1992): 375–379.

H. S. Smith and S. X. Wu, “Persistent Pain after Breast Cancer Treatment,” Annals of Palliative Medicine 1, no. 3 (2013): 182–194.

T. S. Alster and E. L. Tanzi, “Hypertrophic Scars and Keloids,” American Journal of Clinical Dermatology 4, no. 4 (2003): 235–243.

M. G. Khouri et al., “Cancer Therapy – Induced Cardiac Toxicity in Early Breast Cancer,” Circulation 126, no. 23 (2012): 2749–2763.

I. F. Tannock et al., “Cognitive Impairment Associated with Chemotherapy for Cancer: Report of a Workshop,” Journal of Clinical Oncology 22, no. 11 (2004): 2233–2239.

M. Ramalho et al., “Cognitive Impairment in the First Year after Breast Cancer Diagnosis: A Prospective Cohort Study,” The Breast 32 (2017): 173–178.

D. H. Silverman et al. “Abnormal Regional Brain Metabolism in Breast Cancer Survivors after Adjuvant Chemotherapy Is Associated with Cognitive Changes,” Proceedings of the American Society of Clinical Oncology 22 (2003).

S. B. Schagen et al., “Change in Cognitive Function after Chemotherapy: A Prospective Longitudinal Study in Breast Cancer Patients,” Journal of the National Cancer Institute 98, no. 23 (2006): 1742–1745.

X. Chen et al., “Decision-Making Impairments in Breast Cancer Patients Treated with Tamoxifen,” Hormones and Behavior 66, no. 2 (2014): 449–456.

T. A. Ahles and A. J. Saykin, “Candidate Mechanisms for Chemotherapy-Induced Cognitive Changes,” Nature Reviews: Cancer 7, no. 3 (March 2007): 192–201.

R. J. Ferguson et al., “Cognitive‐Behavioral Management of Chemotherapy‐Related Cognitive Change,” Psycho‐Oncology 16, no. 8 (2007): 772–777.

Early Breast Cancer Trialists’ Collaborative Group, “Tamoxifen for Early Breast Cancer: An Overview of the Randomised Trials,” The Lancet 351, no. 9114 (May 1998): 1451–1467.

M. Schaapveld et al., “Risk of New Primary Nonbreast Cancers after Breast Cancer Treatment: A Dutch Population-Based Study,” Journal of Clinical Oncology 26, no. 8 (March 2008): 1239–1246.

E. Diamandidou et al., “Treatment-Related Leukemia in Breast Cancer Patients Treated with Fluorouracil-doxorubicin-cyclophosphamide Combination Adjuvant Chemotherapy: The University of Texas M. D. Anderson Cancer Center Experience,” Journal of Clinical Oncology 14, no. 10 (October 1996): 2722–2730.

T. Grantzau and J. Overgaard, “Risk of Second Non-breast Cancer among Patients Treated with and without Postoperative Radiotherapy for Primary Breast Cancer: A Systematic Review and Meta-analysis of Population-Based Studies Including 522,739 Patients,” Radiotherapy and Oncology 121, no. 3 (2016): 402–413.

H. G. Björneklett et al., “A Randomised Controlled Trial of Support Group Intervention after Breast Cancer Treatment: Results on Anxiety and Depression,” Acta Oncologica 51, no. 2 (February 2012): 198–207; H. G. Björneklett et al., “LongTerm Follow-Up of a Randomized Study of Support Group Intervention in Women with Primary Breast Cancer,” Journal of Psychosomatic Research 74, no. 4 (April 2013): 346–353.

R. Jagsi et al., “Patient-Reported Quality of Life and Satisfaction with Cosmetic Outcomes after Breast Conservation and Mastectomy with and without Reconstruction: Results of a Survey of Breast Cancer Survivors,” Annals of Surgery 261, no. 6 (2015): 1198.

M. E. Mast, “Survivors of Breast Cancer: Illness Uncertainty, Positive Reappraisal, and Emotional Distress,” Oncology Nursing Forum 25, no. 3 (April 1998): 555–562.

R. R. Bouknight, C. J. Bradley, and Z. Luo, “Correlates of Return to Work for Breast Cancer Survivors,” Journal of Clinical Oncology 24, no. 3 (2006): 345–353.

J. H. Lee et al., “US Screening for Detection of Nonpalpable Locoregional Recurrence after Mastectomy,” European Journal of Radiology 82, no. 3 (2013): 485–489.

I. L. Wapnir et al., “Prognosis after Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials,” Journal of Clinical Oncology 24, no. 13 (May 2006): 2028–2037.

S. J. Anderson et al., “Prognosis after Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer,” Journal of Clinical Oncology 27, no. 15 (2009): 2466–2473.

M. Trombetta et al., “Breast Conservation Surgery and Interstitial Brachytherapy in the Management of Locally Recurrent Carcinoma of the Breast: The Allegheny General Hospital Experience,” Brachytherapy 7, no. 1 (January – March 2008): 29–36; T. E. Alpert et al., “Ipsilateral Breast Tumor Recurrence after Breast Conservation Therapy: Outcomes of Salvage Mastectomy vs. Salvage Breast-Conserving Surgery and Prognostic Factors for Salvage Breast Preservation,” International Journal of Radiation Oncology * Biology * Physics 63 (2005): 845–851.

J. O’Shaughnessy, “Extending Survival with Chemotherapy in Metastatic Breast Cancer,” The Oncologist 10, no. 3 (2005): 20–29.

A. B. Mariotto et al., “Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States,” Cancer Epidemiology and Prevention Biomarkers 26, no. 6 (2017): 809–815.

Early Breast Cancer Trialists’ Collaborative Group, “Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” The Lancet 365, no. 9472 (2005): 1687–1617.